ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?

SIMPLE SUMMARY: Endocrine therapy (ET) remains the mainstay of treatment for Hormone Receptor-positive breast cancer, both in the early and advanced settings. The acquisition of mutations in the ESR1 gene encoding the estrogen receptor represents one of the main resistance mechanisms to ET. A conven...

Descripción completa

Detalles Bibliográficos
Autores principales: Betz, Margaux, Massard, Vincent, Gilson, Pauline, Witz, Andréa, Dardare, Julie, Harlé, Alexandre, Merlin, Jean-Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649433/
https://www.ncbi.nlm.nih.gov/pubmed/37958343
http://dx.doi.org/10.3390/cancers15215169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649433/
https://www.ncbi.nlm.nih.gov/pubmed/37958343
http://dx.doi.org/10.3390/cancers15215169

Ejemplares similares